Quick answer
What is Maridebart cafraglutide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Maridebart cafraglutide is not a peptide, grouped on this site under Incretin receptor agonists, and the 5 research records kept here are 1 from a study in rats or mice, 2 from trials in people and 2 that do not state what kind of study it is.
The literature search returned 13 records. This site keeps 5 of them, which is 38 per cent of what came back.
What it is
Maridebart cafraglutide is indexed here despite not being a peptide, because the same research literature and the same searches cover it. This site puts it in the Incretin receptor agonists group.
An antibody-peptide conjugate described in the retrieved records as a GIP receptor antagonist and GLP-1 receptor agonist.[1]
Stated in the title of the cited 2026 Journal of Medicinal Chemistry paper.
What kind of records
No public chemistry record was found under this name, so the entry describes a preparation, a protein or a mixture rather than one defined molecule.
That sentence is produced by counting, not by reading. What was counted: PubChem returned no compound record for this name, so the subject is a preparation, protein or mixture rather than a defined small molecule; identity fields are unsourced.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 8 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Discovery of AMG 133, a Glucose-Dependent Insulinotropic Polypeptide Receptor Antagonist and Glucagon-Like Peptide 1 Receptor Agonist Antibody-Drug Conjugate for the Treatment of Obesity. Journal of medicinal chemistry (2026). pmid:41941715